It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
To evaluate the diagnostic accuracy of the different tests commonly used in the evaluation of adrenal incidentalomas (AIs) for the identification of autonomous cortisol secretion (ACS) and comorbidities potentially related to ACS. In a retrospective study of patients with AIs ≥ 1 cm, we evaluated the diagnostic reliability and validity of the dexamethasone suppression test (DST), urinary free cortisol (UFC), ACTH, late-night salivary cortisol (LNSC), and dehydroepiandrosterone-sulphate (DHEAS) for the diagnosis of comorbidities potentially related to ACS. Diagnostic indexes were also calculated for UFC, ACTH, LNSC, and DHEAS considering DST as the gold standard test for the diagnosis of ACS, using three different post-DST cortisol thresholds (138 nmol/L, 50 nmol/L and 83 nmol/L). We included 197 patients with AIs in whom the results of the five tests abovementioned were available. At diagnosis, 85.9% of patients with one or more AIs had any comorbidity potentially related to ACS, whereas 9.6% had ACS as defined by post-DST cortisol > 138 nmol/L. The reliability of UFC, ACTH, LNSC, and DHEAS for the diagnosis of ACS was low (kappa index < 0.30). Of them, LNSC reached the highest diagnosis accuracy for ACS identification (AUC = 0.696 [95% CI 0.626–0.759]). The diagnostic performances of these tests for comorbidities potentially related to ACS was poor; of them, the DST was the most accurate (AUC = 0.661 [95% CI 0.546–0.778]) and had the strongest association with these comorbidities (OR 2.6, P = 0.045). Patients presenting with increased values of both DST and LNSC had the strongest association with hypertension (OR 7.1, P = 0.002) and with cardiovascular events (OR 3.6, P = 0.041). In conclusion, LNSC was the test showing the highest diagnosis accuracy for the identification of ACS when a positive DST was used as the gold standard for its diagnosis. The DST test showed the strongest association with comorbidities potentially related to ACS. The definition of ACS based on the combination of elevated DST and LNSC levels improved the identification of patients with increased cardiometabolic risk.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; García Cano Ana 2 ; Jiménez, Mendiguchía Lucía 2 ; Escobar-Morreale, Héctor F 3 ; Valderrábano Pablo 4 1 Hospital Universitario Ramón y Cajal, Neuroendocrinology Unit, Department of Endocrinology & Nutrition, Madrid, Spain (GRID:grid.411347.4) (ISNI:0000 0000 9248 5770); Universidad de Alcalá, Madrid, Spain (GRID:grid.7159.a) (ISNI:0000 0004 1937 0239); Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain (GRID:grid.420232.5) (ISNI:0000 0004 7643 3507)
2 Hospital Universitario Ramón y Cajal, Department of Biochemistry, Madrid, Spain (GRID:grid.411347.4) (ISNI:0000 0000 9248 5770)
3 Hospital Universitario Ramón y Cajal, Department of Endocrinology & Nutrition, Madrid, Spain (GRID:grid.411347.4) (ISNI:0000 0000 9248 5770); Universidad de Alcalá, Madrid, Spain (GRID:grid.7159.a) (ISNI:0000 0004 1937 0239); Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain (GRID:grid.420232.5) (ISNI:0000 0004 7643 3507); Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (CIBAERDEM), Madrid, Spain (GRID:grid.430579.c) (ISNI:0000 0004 5930 4623)
4 Hospital Universitario Ramón y Cajal, Department of Endocrinology & Nutrition, Madrid, Spain (GRID:grid.411347.4) (ISNI:0000 0000 9248 5770); Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain (GRID:grid.420232.5) (ISNI:0000 0004 7643 3507)




